Food and Drug Administration

Arthritis Advisory Committee


August 16, 2001

BLA STN 103950 Kineret® , (anakinra), Amgen, Inc.

FDA Perspective, Raymond P. Donnelly, Ph.D.   ppt   htm

Biologic License Application: anakinra (KINERET) for rheumatoid arthritis, CBER   ppt   htm


The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Amgen Inc.  Presentation   ppt   pdf